BioCryst Selling General Administrative vs Net Income Analysis

BCRX Stock  USD 7.35  0.00  0.00%   
BioCryst Pharmaceuticals financial indicator trend analysis is way more than just evaluating BioCryst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioCryst Pharmaceuticals is a good investment. Please check the relationship between BioCryst Pharmaceuticals Selling General Administrative and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Selling General Administrative vs Net Income

Selling General Administrative vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioCryst Pharmaceuticals Selling General Administrative account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between BioCryst Pharmaceuticals' Selling General Administrative and Net Income is -0.9. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Net Income in the same time period over historical financial statements of BioCryst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of BioCryst Pharmaceuticals' Selling General Administrative and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of BioCryst Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Selling General Administrative i.e., BioCryst Pharmaceuticals' Selling General Administrative and Net Income go up and down completely randomly.

Correlation Coefficient

-0.9
Relationship DirectionNegative 
Relationship StrengthSignificant

Selling General Administrative

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in BioCryst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of BioCryst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses327.6M412.7M430.5M452.0M
Cost Of Revenue7.3M6.6M4.7M9.2M

BioCryst Pharmaceuticals fundamental ratios Correlations

0.930.880.87-0.630.790.71-0.940.910.750.060.990.950.940.210.90.950.811.0-0.66-0.510.930.640.93-0.66-0.3
0.930.90.82-0.40.860.91-0.930.790.52-0.010.890.870.990.290.970.990.860.94-0.77-0.520.850.820.85-0.54-0.2
0.880.90.95-0.430.920.84-0.930.80.410.210.840.890.890.040.790.920.860.86-0.56-0.40.890.840.88-0.61-0.31
0.870.820.95-0.540.890.7-0.950.870.490.190.860.940.810.040.70.850.820.86-0.39-0.370.960.750.96-0.72-0.41
-0.63-0.4-0.43-0.54-0.37-0.070.58-0.61-0.8-0.17-0.68-0.68-0.410.32-0.32-0.44-0.53-0.610.110.57-0.630.0-0.660.60.43
0.790.860.920.89-0.370.86-0.90.70.280.120.750.830.840.120.770.860.940.79-0.53-0.480.840.880.83-0.59-0.25
0.710.910.840.7-0.070.86-0.790.530.110.030.640.670.880.320.870.880.810.71-0.69-0.450.670.950.65-0.37-0.13
-0.94-0.93-0.93-0.950.58-0.9-0.79-0.88-0.57-0.06-0.92-0.98-0.92-0.16-0.84-0.95-0.88-0.940.520.52-0.97-0.77-0.970.670.43
0.910.790.80.87-0.610.70.53-0.880.76-0.050.920.930.810.090.740.830.630.92-0.48-0.230.930.50.93-0.64-0.34
0.750.520.410.49-0.80.280.11-0.570.76-0.070.810.680.550.020.540.560.380.76-0.42-0.350.63-0.020.65-0.52-0.2
0.06-0.010.210.19-0.170.120.03-0.06-0.05-0.070.080.05-0.06-0.13-0.03-0.030.16-0.020.21-0.180.00.060.010.0-0.39
0.990.890.840.86-0.680.750.64-0.920.920.810.080.950.90.150.860.920.770.99-0.63-0.490.920.560.92-0.68-0.31
0.950.870.890.94-0.680.830.67-0.980.930.680.050.950.880.110.780.910.820.95-0.47-0.480.990.660.99-0.72-0.44
0.940.990.890.81-0.410.840.88-0.920.810.55-0.060.90.880.320.971.00.840.95-0.77-0.520.860.790.85-0.53-0.2
0.210.290.040.040.320.120.32-0.160.090.02-0.130.150.110.320.450.280.10.22-0.26-0.170.090.270.080.21-0.05
0.90.970.790.7-0.320.770.87-0.840.740.54-0.030.860.780.970.450.950.770.9-0.81-0.510.750.730.75-0.42-0.16
0.950.990.920.85-0.440.860.88-0.950.830.56-0.030.920.911.00.280.950.850.96-0.74-0.510.890.80.89-0.57-0.23
0.810.860.860.82-0.530.940.81-0.880.630.380.160.770.820.840.10.770.850.8-0.56-0.740.810.780.81-0.59-0.24
1.00.940.860.86-0.610.790.71-0.940.920.76-0.020.990.950.950.220.90.960.8-0.68-0.50.930.630.93-0.66-0.27
-0.66-0.77-0.56-0.390.11-0.53-0.690.52-0.48-0.420.21-0.63-0.47-0.77-0.26-0.81-0.74-0.56-0.680.36-0.44-0.53-0.430.29-0.4
-0.51-0.52-0.4-0.370.57-0.48-0.450.52-0.23-0.35-0.18-0.49-0.48-0.52-0.17-0.51-0.51-0.74-0.50.36-0.43-0.34-0.450.380.16
0.930.850.890.96-0.630.840.67-0.970.930.630.00.920.990.860.090.750.890.810.93-0.44-0.430.681.0-0.76-0.4
0.640.820.840.750.00.880.95-0.770.5-0.020.060.560.660.790.270.730.80.780.63-0.53-0.340.680.66-0.44-0.16
0.930.850.880.96-0.660.830.65-0.970.930.650.010.920.990.850.080.750.890.810.93-0.43-0.451.00.66-0.77-0.4
-0.66-0.54-0.61-0.720.6-0.59-0.370.67-0.64-0.520.0-0.68-0.72-0.530.21-0.42-0.57-0.59-0.660.290.38-0.76-0.44-0.770.1
-0.3-0.2-0.31-0.410.43-0.25-0.130.43-0.34-0.2-0.39-0.31-0.44-0.2-0.05-0.16-0.23-0.24-0.27-0.40.16-0.4-0.16-0.40.1
Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets175.3M334.7M588.2M550M517.0M542.8M
Short Long Term Debt Total84.7M150.9M593.2M741.5M848.7M891.1M
Other Current Liab36.3M55.6M70.0M87.2M126.4M132.8M
Total Current Liabilities92.3M105.7M103.7M105.5M150.0M157.5M
Total Stockholder Equity(840.6M)(1.0B)(1.2B)(1.5B)(455.5M)(432.8M)
Property Plant And Equipment Net7.3M7.1M8.7M15.4M20.9M22.0M
Net Debt(29.5M)(147.4M)88.8M436.7M714.5M750.2M
Retained Earnings(840.6M)(1.0B)(1.2B)(1.5B)(1.7B)(1.6B)
Accounts Payable14.0M18.7M27.8M14.4M20.9M21.9M
Cash114.2M272.1M504.4M304.8M110.6M65.7M
Non Current Assets Total10.9M10.9M22.0M33.5M21.0M24.6M
Cash And Short Term Investments136.2M300.4M514.4M442.4M389.0M408.4M
Common Stock Shares Outstanding115.6M167.3M179.1M185.9M192.2M201.8M
Liabilities And Stockholders Equity(703.6M)(669.5M)(512.4M)(610.0M)517.0M542.8M
Non Current Liabilities Total44.7M248.3M591.4M739.1M822.5M863.6M
Other Current Assets4.4M5.5M13.3M14.1M21.3M22.4M
Other Stockholder Equity(1.6M)(1.8M)1.1B1.2B1.2B1.3B
Total Liab137.0M354.0M695.1M844.6M972.5M1.0B
Property Plant And Equipment Gross7.3M7.1M8.7M25.0M19.1M20.1M
Total Current Assets164.3M323.8M566.1M516.5M496.0M520.8M
Accumulated Other Comprehensive Income39K3K177K26K1.3M1.4M
Short Term Debt40.0M31.2M1.8M2.4M2.6M2.5M
Non Currrent Assets Other3.6M3.8M6.5M(33.5M)80K76K
Common Stock Total Equity1.1M1.5M1.8M1.8M2.1M2.2M
Short Term Investments22.1M28.2M3.2M119.5M278.3M292.3M
Common Stock1.5M1.8M1.8M1.9M2.1M2.2M
Current Deferred Revenue2.1M150K1.4M1.2M1.1M1.0M
Property Plant Equipment7.3M7.1M15.2M15.4M17.7M18.6M
Other Assets2.0M978K588.2M550M632.5M664.1M
Net Receivables22.1M8.6M29.4M50.6M57.0M59.8M
Inventory1.6M7.0M15.8M27.5M28.7M30.1M
Net Tangible Assets82.9M109.3M(147.0M)(294.6M)(265.1M)(251.9M)
Long Term Debt41.3M119.7M585.5M733.3M811.3M851.8M
Retained Earnings Total Equity(732.0M)(840.6M)(1.0B)(1.2B)(1.1B)(1.0B)
Long Term Debt Total28.1M41.3M119.7M136.1M156.5M164.3M
Capital Surpluse780.4M877.3M1.0B1.1B1.3B745.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.